Form Bio

Form Bio is an AI-driven life sciences company dedicated to accelerating genetic medicine and genome engineering. Founded in 2022 as the first spinout from Colossal Biosciences, Form Bio expands foundational multi-species genome engineering technology into human genetic medicines. The company brings together AI and software engineers, bioinformaticians, molecular and cellular biologists, and drug developers to help partners develop safer, smarter, and faster therapies for patients.

Form Bio serves a range of life sciences organizations, including gene therapy companies such as Taysha Gene Therapies and Solid Biosciences, as well as genome engineering innovators like Colossal Biosciences. The company's work spans the full development continuum, from early discovery through preclinical and IND stages into clinical translation, with active pipeline programs in Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2G, and Alzheimer's Disease.

Genetic Medicine Capabilities

• Vector & Payload Design: FORMsightAI optimizes AAV vector genomes and large or complex payloads, improving genome integrity, reducing truncations, and enabling tunable expression.
• AI-Powered Accuracy: AI-augmented coding sequence (CDS) optimization and rational design enhance manufacturability, lower safety risks, and reduce CpG-driven immunogenicity.
• Maximizing Efficacy: Expression tuning and codon optimization improve CAR-T persistence and potency, enabling safer and more effective therapies.
• Scalable Manufacturing: Form Bio has demonstrated up to 5x improvements in genome integrity and 4.4x yield gains, directly lowering cost of goods sold (COGS) and supporting efficient clinical translation.

Genome Engineering

• Next-Gen Editing Tools: Leverages breakthroughs in CRISPR and emerging genome engineering technologies to design and optimize precise genetic modifications across any genome.
• AI-Powered Analysis: Combines AI-driven insights with expert biological interpretation to identify and validate key genotype-to-phenotype relationships for engineering desired traits.
• Accelerate Validation: Validation analysis using amplicon or whole-genome sequencing to measure on-target efficiency and predict impactful off-target effects.

Protein Engineering

• Enzyme Design & Optimization: Enhances catalytic activity, increases turnover, improves substrate affinity, and fine-tunes active-site geometry, even for difficult substrates.
• Multimer & Interface Engineering: Designs and optimizes protein–protein interfaces to control assembly, boost stability, enable cooperative activity, and create custom multivalent architectures.
• De Novo Scaffolds & Mini-Binders: Builds fully engineered, ultra-stable scaffolds and high-affinity binders with novel specificities and proprietary molecular architectures.
• AI-Driven Functional Prediction: Uses advanced modeling to forecast structural stability, binding performance, and functional outcomes to accelerate design cycles.

Key Applications

• Genome Integrity Analysis: Provides a structured approach for characterizing genetic medicines, offering drug product insights into the distribution of full versus partial genomes and contaminated species, and mapping truncation hotspots to the vector map to uncover DNA complexities that can be mitigated through data-driven design.
• Codon Optimization: Powered by the proprietary FORMsightAI model, this application clarifies biological goals such as boosting protein expression, enhancing manufacturability, and improving safety. The model optimizes across multiple objectives while managing tradeoffs such as increasing expression versus minimizing truncations.
• Genome Assembly: Accurately reconstructs genomes by piecing together DNA fragments into contiguous sequences, supporting downstream variant detection, functional annotation, and comparative genomics.

Solutions Portfolio

• Drug Substance Insights
• Capsid Analysis
• Bioinformatics Analysis
• Gene Editing
• AI Model Development
• Protein Engineering

Form Bio is recognized by leading scientists and industry executives as a critical partner in the future of bioengineering. With endorsements from Harvard Medical School Professor George Church and technology leaders at Taysha Gene Therapies and Solid Biosciences, Form Bio continues to push the boundaries of what is possible in genetic medicine and genome engineering.